Gene Delivery System Market Insights: Size, Share, Growth Analysis & Forecast (2024-2029)
The market report provided a comprehensive analysis segmented by Delivery System (Viral Gene Delivery System, Non-Viral Gene Delivery System, Combined Hybrid System); by Application (Infectious Diseases, Oncology, Ophthalmology, Urology, Diabetes, CNS); by Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa).
Outlook
- The gene delivery system market is estimated to be at USD 5,054.86 Mn in 2024 and is anticipated to reach USD 7,242.01 Mn in 2029.
- The gene delivery system market is registering a CAGR of 7.46% during the forecast period of 2024-2029.
- The global gene delivery system market is experiencing rapid growth, driven by its expanding applications in gene therapy, vaccine development, and precision medicine.
Request a free sample.
Ecosystem
- The participants in the global gene delivery system industry are always developing their strategies and leading the market through innovation and strategic partnerships to preserve a competitive advantage.
- These companies are investing in advanced delivery platforms to enhance gene therapy efficacy, along with strategic collaborations between biotech firms and pharmaceutical giants to maintain a competitive edge in the market.
- Several important entities in the gene delivery system market include Novartis AG; Oxford Biomedica Plc.; Shanghai Sunway Biotech Co., Ltd.; Pfizer Inc.; Johnson & Johnson Services, Inc.; and others.
Ask for customization.
Findings
| Attributes | Values |
|---|---|
| Historical Period | 2018-2022 |
| Base Year | 2023 |
| Forecast Period | 2024-2029 |
| Market Size (2024) | USD 5,054.86 Mn |
| Market Size (2029) | USD 7,242.01 Mn |
| Growth Rate | 7.46% CAGR from 2024 to 2029 |
| Key Segments | Delivery System (Viral Gene Delivery System, Non-Viral Gene Delivery System, Combined Hybrid System); Application (Infectious Diseases, Oncology, Ophthalmology, Urology, Diabetes, CNS); Geography (North America, South America, Asia Pacific, Europe, The Middle East, Africa) |
| Key Vendors | Novartis AG; Oxford Biomedica Plc.; Shanghai Sunway Biotech Co., Ltd.; Pfizer Inc.; Johnson & Johnson Services, Inc. |
| Key Countries | The US; Canada; Mexico; Brazil; China; India; Japan; The UK; Germany; Italy; France; Spain; South Africa |
| Largest Market | North America |
Get a free quote.
Trends
- CRISPR-Cas System Advancements: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-based gene editing systems are showing promise in gene therapy. In 2023, Editas Medicine announced successful preclinical trials using a novel CRISPR delivery system to treat sickle cell anemia, highlighting advancements in precision gene delivery techniques.
- Focus on Rare Diseases: The focus on developing gene therapies for rare genetic disorders is growing. In 2023, Bluebird Bio received FDA approval for its gene therapy aimed at treating beta-thalassemia, utilizing an advanced gene delivery system that specifically targets the defective gene.
- Personalized Medicine Advancements: The rise of personalized medicine is expanding the scope for tailored gene delivery systems. In 2023, Sangamo Therapeutics partnered with Pfizer to develop personalized gene therapies for hemophilia, showing the growing importance of individualized treatment approaches.
Speak to analyst.
Catalysts
- Rising Incidence of Genetic Disorders: Gene delivery systems are in high demand because of the increasing prevalence of genetic disorders like cystic fibrosis and hemophilia. Advanced therapies are needed as per the World Health Organization, over 400 million people have rare genetic disorders.
- Breakthroughs in Gene Therapy: Gene therapy has undergone significant advancements that have redefined treatment methods for genetic diseases. In 2023, the FDA cleared a gene therapy developed by Novartis to treat spinal muscular atrophy – an indication of how much gene delivery systems can change lives.
- Government Funding: Government initiatives supporting gene therapy research are boosting the market. In 2023, the U.S. National Institutes of Health allocated USD 250 million for gene therapy research, accelerating the development and commercialization of gene delivery systems.
Inquire before buying.
Restraints
- High Development Costs: Developing gene delivery systems is capital-intensive, with significant costs associated with R&D and clinical trials. In 2023, Bluebird Bio has been spending over USD 500 million on the development of its beta-thalassemia gene therapy, illustrating the financial burden faced by companies in this market.
- Regulatory Hurdles: Challenges arise from companies navigating the complex regulatory landscape for gene therapies. Europe has delayed CRISPR Therapeutics’ regulatory approvals for its gene editing therapy in 2023, making it obvious that it is not easy to bring a new product into the market.
- Safety Concerns: Viral vectors pose ongoing safety concerns, such as potential immune reactions and insertional mutagenesis. In 2023, there were also cases where Orchard Therapeutics faced failures in their clinical trials due to viral vector-based gene therapy causing negative immune responses.
Hotspot
Explore purchase options.
Table of Contents
| 1.       Introduction 1.1.    Research Methodology 1.2.    Scope of the Study 2.       Market Overview / Executive Summary 2.1.    Global Gene Delivery System Market (2018 – 2022) 2.2.    Global Gene Delivery System Market (2023 – 2029) 3.       Market Segmentation 3.1.    Global Gene Delivery System Market by Delivery System 3.1.1. Viral Gene Delivery System 3.1.2. Non-Viral Gene Delivery System 3.1.3. Combined Hybrid System 3.2.    Global Gene Delivery System Market by Application 3.2.1. Infectious Diseases 3.2.2. Oncology 3.2.3. Ophthalmology 3.2.4. Urology 3.2.5. Diabetes 3.2.6. CNS 4.       Regional Segmentation 4.1.    North America 4.1.1. The US 4.1.2. Canada 4.1.3. Mexico 4.2.    South America 4.2.1. Brazil 4.2.2. Argentina 4.2.3. Colombia 4.2.4. Chile 4.2.5. Rest of South America 4.3.    Asia Pacific 4.3.1. China 4.3.2. India 4.3.3. Japan 4.3.4. South Korea 4.3.5. Rest of Asia Pacific 4.4.    Europe 4.4.1. The UK 4.4.2. Germany 4.4.3. Italy 4.4.4. France 4.4.5. Spain 4.4.6. Rest of Europe 4.5.    The Middle East 4.5.1. Turkey 4.5.2. UAE 4.5.3. Saudi Arabia 4.5.4. Rest of the Middle East 4.6.    Africa 4.6.1. Egypt 4.6.2. South Africa 4.6.3. Rest of Africa 5.       Value Chain Analysis of the Global Gene Delivery System Market 6.       Porter Five Forces Analysis 6.1.    Threats of New Entrants 6.2.    Threats of Substitutes 6.3.    Bargaining Power of Buyers 6.4.    Bargaining Power of Suppliers 6.5.    Competition in the Industry 7.       Trends, Drivers and Challenges Analysis 7.1.    Market Trends 7.1.1.    Market Trend 1 7.1.2.    Market Trend 2 7.1.3.    Market Trend 3 7.2.    Market Drivers 7.2.1.    Market Driver 1 7.2.2.    Market Driver 2 7.2.3.    Market Driver 3 7.3.    Market Challenges 7.3.1.    Market Challenge 1 7.3.2.    Market Challenge 2 7.3.3.    Market Challenge 3 8.       Opportunities Analysis 8.1.    Market Opportunity 1 8.2.    Market Opportunity 2 8.3.    Market Opportunity 3 9.       Competitive Landscape 9.1.    Novartis AG 9.2.    Oxford Biomedica Plc. 9.3.    Shanghai Sunway Biotech Co., Ltd. 9.4.    Pfizer Inc. 9.5.    Johnson & Johnson Services, Inc. 9.6.    Company 6 9.7.    Company 7 9.8.    Company 8 9.9.    Company 9 9.10.  Company 10 |
Know the research methodology.
Gene Delivery System Market – FAQs
1. What is the current size of the gene delivery system market?
Ans. In 2024, the gene delivery system market size is $5,054.86 Mn.
2. Who are the major vendors in the gene delivery system market?
Ans. The major vendors in the gene delivery system market are Novartis AG; Oxford Biomedica Plc.; Shanghai Sunway Biotech Co., Ltd.; Pfizer Inc.; Johnson & Johnson Services, Inc.
3. Which segments are covered under the gene delivery system market segments analysis?
Ans. The gene delivery system market report offers in-depth insights into Delivery System, Application, and Geography.